BioAge Labs Employees

As of December 31, 2024, BioAge Labs had 64 total employees, including 62 full-time and 2 part-time employees. The number of employees increased by 8 or 14.29% compared to the previous year.

Employees

Change (1Y)

Growth (1Y)

14.29%

Revenue / Employee

$92,453

Profits / Employee

-$1,184,234

Market Cap

847.16M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	64	8	14.29%
Dec 31, 2023	56	-	-

Related Stocks

Company Name	Employees
Evotec SE	4,788
Tilray Brands	2,842
Amphastar Pharmaceuticals	1,976
Alvotech	1,012
Pacira BioSciences	790
Cronos Group	459
Collegium Pharmaceutical	423
Harrow	382

Employee Rankings

BIOA News

6 weeks ago - BioAge Announces Pricing of Upsized $115.0 Million Public Offering - GlobeNewsWire
6 weeks ago - BioAge Announces Proposed Public Offering - GlobeNewsWire
6 weeks ago - BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 - GlobeNewsWire
7 weeks ago - BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk - GlobeNewsWire
3 months ago - BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - GlobeNewsWire
3 months ago - BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
4 months ago - BioAge Labs to Present at Jefferies Global Healthcare Conference in London - GlobeNewsWire
6 months ago - HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor - PRNewsWire

More News